Increased Cytoplasmic CD138 Expression Is Associated with Aggressive Characteristics in Prostate Cancer and Is an Independent Predictor for Biochemical Recurrence
Standard
Increased Cytoplasmic CD138 Expression Is Associated with Aggressive Characteristics in Prostate Cancer and Is an Independent Predictor for Biochemical Recurrence. / Kind, Simon; Kluth, Martina; Hube-Magg, Claudia; Möller, Katharina; Makrypidi-Fraune, Georgia; Lutz, Florian; Lennartz, Maximilian; Rico, Sebastian Dwertmann; Schlomm, Thorsten; Heinzer, Hans; Höflmayer, Doris; Weidemann, Sören; Uhlig, Ria; Huland, Hartwig; Graefen, Markus; Bernreuther, Christian; Tsourlakis, Maria Christina; Minner, Sarah; Dum, David; Hinsch, Andrea; Lübke, Andreas M; Simon, Ronald; Sauter, Guido; Marx, Andreas; Polonski, Adam.
in: BIOMED RES INT , Jahrgang 2020, 2020, S. 5845374.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Increased Cytoplasmic CD138 Expression Is Associated with Aggressive Characteristics in Prostate Cancer and Is an Independent Predictor for Biochemical Recurrence
AU - Kind, Simon
AU - Kluth, Martina
AU - Hube-Magg, Claudia
AU - Möller, Katharina
AU - Makrypidi-Fraune, Georgia
AU - Lutz, Florian
AU - Lennartz, Maximilian
AU - Rico, Sebastian Dwertmann
AU - Schlomm, Thorsten
AU - Heinzer, Hans
AU - Höflmayer, Doris
AU - Weidemann, Sören
AU - Uhlig, Ria
AU - Huland, Hartwig
AU - Graefen, Markus
AU - Bernreuther, Christian
AU - Tsourlakis, Maria Christina
AU - Minner, Sarah
AU - Dum, David
AU - Hinsch, Andrea
AU - Lübke, Andreas M
AU - Simon, Ronald
AU - Sauter, Guido
AU - Marx, Andreas
AU - Polonski, Adam
N1 - Copyright © 2020 Simon Kind et al.
PY - 2020
Y1 - 2020
N2 - Syndecan-1 (CD138) is a transmembrane proteoglycan expressed in various normal and malignant tissues. It is of interest due to a possible prognostic effect in tumors and its role as a target for the antibody-drug conjugate indatuximab ravtansine. Here, we analyzed 17,747 prostate cancers by immunohistochemistry. Membranous and cytoplasmic CD138 staining was separately recorded. In normal prostate glands, CD138 staining was limited to basal cells. In cancers, membranous CD138 positivity was seen in 19.6% and cytoplasmic CD138 staining in 11.2% of 12,851 interpretable cases. A comparison with clinico-pathological features showed that cytoplasmic CD138 staining was more linked to unfavorable tumor features than membranous staining. Cytoplasmic CD138 immunostaining was associated with high tumor stage (p < 0.0001), high Gleason grade (p < 0.0001), nodal metastases (p < 0.0001), positive surgical margin (p < 0.0001), and biochemical recurrence (p < 0.0001). This also holds true for both V-ets avian erythroblastosis virus E26 oncogene homolog (ERG) fusion positive and ERG fusion negative tumors although the cytoplasmic CD138 expression was markedly more frequent in ERG positive than in ERG negative tumors (p < 0.0001). Comparison with 11 previously analyzed chromosomal deletions identified a conspicuous association between cytoplasmic CD138 expression and 8p deletions (p < 0.0001) suggesting a possible functional interaction of CD138 with one or several 8p genes. Multivariate analysis revealed the cytoplasmic CD138 expression as an independent prognostic parameter in all cancers and in the ERG positive subgroup. In summary, our study indicates the cytoplasmic CD138 expression as a strong and independent predictor of poor prognosis in prostate cancer. Immunohistochemical measurement of CD138 protein may thus-perhaps in combination with other parameters-become clinically useful in the future.
AB - Syndecan-1 (CD138) is a transmembrane proteoglycan expressed in various normal and malignant tissues. It is of interest due to a possible prognostic effect in tumors and its role as a target for the antibody-drug conjugate indatuximab ravtansine. Here, we analyzed 17,747 prostate cancers by immunohistochemistry. Membranous and cytoplasmic CD138 staining was separately recorded. In normal prostate glands, CD138 staining was limited to basal cells. In cancers, membranous CD138 positivity was seen in 19.6% and cytoplasmic CD138 staining in 11.2% of 12,851 interpretable cases. A comparison with clinico-pathological features showed that cytoplasmic CD138 staining was more linked to unfavorable tumor features than membranous staining. Cytoplasmic CD138 immunostaining was associated with high tumor stage (p < 0.0001), high Gleason grade (p < 0.0001), nodal metastases (p < 0.0001), positive surgical margin (p < 0.0001), and biochemical recurrence (p < 0.0001). This also holds true for both V-ets avian erythroblastosis virus E26 oncogene homolog (ERG) fusion positive and ERG fusion negative tumors although the cytoplasmic CD138 expression was markedly more frequent in ERG positive than in ERG negative tumors (p < 0.0001). Comparison with 11 previously analyzed chromosomal deletions identified a conspicuous association between cytoplasmic CD138 expression and 8p deletions (p < 0.0001) suggesting a possible functional interaction of CD138 with one or several 8p genes. Multivariate analysis revealed the cytoplasmic CD138 expression as an independent prognostic parameter in all cancers and in the ERG positive subgroup. In summary, our study indicates the cytoplasmic CD138 expression as a strong and independent predictor of poor prognosis in prostate cancer. Immunohistochemical measurement of CD138 protein may thus-perhaps in combination with other parameters-become clinically useful in the future.
U2 - 10.1155/2020/5845374
DO - 10.1155/2020/5845374
M3 - SCORING: Journal article
C2 - 33195694
VL - 2020
SP - 5845374
JO - BIOMED RES INT
JF - BIOMED RES INT
SN - 2314-6133
ER -
